Examples of using Orlistat in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
The majority of orlistat overdose cases received during post-marketing reported either no adverse events
The use of orlistat may be associated with renal stones in patients suffering from chronic kidney disease.
Β-Carotene should not be taken with orlistat, a weight-loss medication, as orlistat can reduce the absorption of β-carotene by as much as 30.
It is plausible that treatment with orlistat can lead to anxiety in anticipation of or secondary to gastrointestinal adverse reactions.
Based on cumulative reviews a total of 7 cases have been reported demonstrating a likely interaction between orlistat and benzodiazepines.
Should a significant overdose of orlistat occur, it is recommended that the patient be observed for 24 hours.
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat(6.2%) compared to placebo 9.0.
The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
If this occurs, consideration could be given to administering orlistat and antiepileptic medicinal products at different times see section 4.5.
The frequencies of adverse reactions identified during post-marketing use of orlistat are not known as these reactions were reported voluntarily from a population of uncertain size.
The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes to renal failure.
The use of orlistat may be associated with kidney stones in patients suffering from chronic kidney disease.
Therefore, in view of available data regarding orlistat, the PRAC considered that changes to the product information were warranted.
Long-term use of orlistat also leads to a modest reduction in blood pressure mean reductions of 2.5
After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
The results were significantly superior in the orlistat group difference in BMI of 0.86 kg/ m2 in favour of orlistat.
The majority of orlistat overdose cases received during post-marketing reported either no adverse reactions or adverse reactions that are similar to those reported with recommended doses of orlistat.
The gastrointestinal adverse reactions identified from clinical trials with orlistat 60 mg of 18 months to 2 years duration were generally mild and transient.
A decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a limited number of healthy volunteers who received orlistat concomitantly.
Therefore orlistat treatment should only be initiated after careful consideration of the possible impact in these patients.